Home Resource Center   Consulting Services DNA Bridges ä , Inc.

Expert consulting to the life sciences, biotechnology, pharmaceutical and diagnostic industries. 

PROFILE

DNA Bridges®, Inc. provides expert consulting and professional services to the life sciences, biotechnology, pharmaceutical and diagnostic industries. Strategic and operational solutions are based on more than 30 years' experience in industry. Experienced in: gene expression, recombinant protein production, patent portfolio management, cell culture manufacturing, clinical diagnostics and strategic planning to assist you in bridging science to products.

Philosophy: 

The DNA Bridges®, Inc. team of consultants is committed to time-saving, cost-effective solutions to help achieve client objectives. Diverse technical and business expertise among our consultants creates a wide range of ideas and perspectives, which offer our clients a competitive advantage.

Business Development

An essential tool for growing a company, a business plan should include seven essential elements: Business Description, The Market, Development & Production, Sales & Marketing, Management Team, Financials, Gap Analysis, and Fatal Flaws. A compelling plan should articulate and leverage an organization's core competencies as well as present an effective and efficient road map to commercial success. A functional plan that supports an overall mission can prove to be instrumental in the search for capital as well as in communication with investors, analysts and prospective partners.

Intellectual Property Management

Intellectual property management is growing in importance. Biotechnology companies have formed and prospered as a result of technology protected with patents. A strong patent estate can be translated into a technology platform that is valued in the market place. In the last 5 to 10 years the importance of patents, copyrights, and trademarks gained more prominence as business leaders hear of the success of IBM. For example, by proactively managing their intellectual property estate, IBM now collects $1 billion in annual revenue.

Strategic Planning

Knowing what the critical business focus is provides a framework for all business activity. Alignment of technology plans, funding-raising plans, and all business activities is a key to strong business growth. Because funding is an essential factor to growth, all sources need to be considered.

Project Management

Keeping a project on time and on target requires effort. Sometimes the science is so time consuming that managing the program is forgotten. Deadlines needed for funding and commercialization are missed because no one was focused on keeping the decision making on track. DNA Bridges®, Inc. will work with your scientists, managing the project so they can focus on what they do best: Science.

Technical Consulting Our core team has more than 50 years of combined experience in technical fields. Our continuing publication record reflects our ongoing involvement in the the scientific process. Furthermore, because we speak both science and business, we can contribute to your technical success. When we need to, we can bring in other technical experts to assure you of the best advice.

 

Principals: Dr. Cori Gorman and Dr. Eileen Gorman
 

Cori M. Gorman, Ph.D., MBA: President

With twenty-five years experience in the biotechnology industry, Dr. Gorman has worked in all aspects of the biotechnology industry, including raising capital, strategic planning and developing infrastructure. She has helped early stage biotechnology companies raise over $ 80 million (federal funds and VCs) and has closed over 25 partnerships in a corporate development capacity. She has used this experience to chair a number of sessions on business models and financing for early stage companies at BIO and Bio-Europe conferences. She has been a guest lecturer on the business of biotechnology at Yale and at Haas Business School, UC Berkeley. Under her vision, DNA Bridges Inc. has expanded its reach beyond the US into Europe and Australia.

Her experience in the biotechnology industry includes a ten-year period at Genentech where she helped to develop of a number of marketed products including Kogenate, Activase, Herceptin, Xolair, and Raptiva. Based on her work at Genentech, Cori is also recognized as a pioneer in the development of monoclonal antibody therapeutics and has co-authored 6 INDs. Upon leaving her position at Genentech, Cori co-founded two biotech start-ups, one of which, Valentis, went public.

Dr. Gorman has an outstanding record of achievement in basic research and drug development. Dr. Cori Gorman is an inventor on nine issued patents in the fields of gene expression and delivery and gene therapy and is recognized as one of the most highly cited people in her field in the last two decades. Dr. Gorman developed the CAT assay, which was the industry standard for more than fifteen years. Her scientific work has received over 10,000 citations

Cori has received several fellowships from such organizations as the American Cancer Society, the National Cancer Institute, the European Molecular Biology Organization and NATO.

Eileen G. Gorman, Ph.D., USPTO Registered Patent Agent: CEO

Dr. Gorman is a recognized expert in technology development from inception to commercialization. She has held leadership positions at the business/technical interface, in research and development, and technical marketing organization in medical products.

Dr. Gorman has served as technical consultant to the legal department for management of intellectual property assets, developed and implemented business strategies. She also provided program evaluation, benchmarking, oversight and management of product development collaborations with academic and industrial partners. Under her lead, 5 products have been commercialized. She possesses unique expertise and familiarity with both the business and the technical side of business development in industrial and academic settings.

For over 15 years, she was a member of the former DuPont Diagnostics, now Siemens. She holds a Ph.D. in chemistry with a specialization in biochemistry, and was a Staff Fellow at NIH. She has authored over 50 papers, chapters, abstracts, corporate reports, and patents.